MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

88.49
-7.42
-7.74%
Closed 19:08 03/03 EST
OPEN
94.60
PREV CLOSE
95.91
HIGH
95.71
LOW
87.00
VOLUME
905.33K
TURNOVER
--
52 WEEK HIGH
121.16
52 WEEK LOW
16.75
MARKET CAP
8.30B
P/E (TTM)
-42.5678
1D
5D
1M
3M
1Y
5Y
Stem Cell Market Trend Survey 2021 with Top Countries Data: Industry Insights by Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen | With Covid 19 Analysis
Mar 03, 2021 (The Expresswire) -- Global “Stem Cell Market” Report 2021 contains a comprehensive analysis of the important segments like market...
The Express Wire · 10h ago
Fate Therapeutics (FATE) Receives a Buy from Leerink Partners
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Fate Therapeutics (FATE) on February 26. The company's shares closed last Tuesday at
SmarterAnalyst · 1d ago
The Renaissance Of The Moonshot Era
Investing in Potentially World-Altering Innovation
Benzinga · 1d ago
T-cell Therapy Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 01, 2021 (Market Insight Reports) -- The Global T-cell Therapy Market is poised to value over USD 18.3 billion by 2027 end at a CAGR of over 14% during...
Market Insight Reports · 2d ago
15 Fastest Growing Biotech Companies in the US
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the ...
Insider Monkey · 4d ago
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
There's been a notable change in appetite for Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares in the week since its...
Simply Wall St. · 5d ago
Fate Therapeutics initiated buy at BofA despite early-stage pipeline
The analysts at Bank of America have initiated the coverage on Fate Therapeutics ([[FATE]] +3.7%) with a buy rating and a price target of $115.00 per share indicating an upside
Seekingalpha · 5d ago
Premarket analyst action - healthcare
Fate Therapeutics (FATE) initiated with a Buy at BofA Securities. PT set to $115, implies a 33% increase from last price.Wedbush analyst David Nierengarten downgraded FATE to Neutral from Outperform
Seekingalpha · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FATE. Analyze the recent business situations of Fate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FATE stock price target is 109.94 with a high estimate of 135.00 and a low estimate of 58.00.
EPS
Institutional Holdings
Institutions: 331
Institutional Holdings: 91.29M
% Owned: 97.34%
Shares Outstanding: 93.78M
TypeInstitutionsShares
Increased
70
6.22M
New
92
2.99M
Decreased
93
9.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Director
J. Scott Wolchko
President/Chief Executive Officer/Director
John Wolchko
Vice Chairman/Independent Director
John Mendlein
Chief Financial Officer
Edward Dulac
Senior Vice President
Sarah Cooley
Chief Scientific Officer
Daniel Shoemaker
Vice President
Yu-Waye Chu
General Counsel/Secretary
Cindy Tahl
Other
Bahram Valamehr
Director
Shefali Agarwal
Director
Robert Hershberg
Independent Director
Timothy Coughlin
Independent Director
Robert Epstein
Independent Director
Karin Jooss
Independent Director
Michael Lee
No Data
  • All
  • Financials
  • Insiders
More
About FATE
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.